Alnylam Pharmaceuticals
ALNY
290 hedge funds and large institutions have $7.7B invested in Alnylam Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 119 increasing their positions, 74 reducing their positions, and 37 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 74
34% more call options, than puts
Call options by funds: $74.5M | Put options by funds: $55.5M
8.42% more ownership
Funds ownership: 91.17% → 99.59% (+8.4%)
8% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 37
0% more funds holding
Funds holding: 290 → 290 (0)
15% less capital invested
Capital invested by funds: $9.06B → $7.7B (-$1.36B)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$127M |
| 2 |
RI
RTW Investments
New York
|
+$105M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
+$78.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$73.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.5M |
Top Sellers
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$29M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$14.8M |
| 3 |
SG Americas Securities
New York
|
-$12.5M |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$10.1M |
| 5 |
T
TOBAM
Paris,
France
|
-$8.85M |
ALNY Hedge Fund Activity: Q2 2019 in Review
290 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2019, worth a combined $7.7B — down 15% from $9.06B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ALNY positions and 37 closed out — a net gain of 3 holders — while 119 added to existing stakes and 74 trimmed.
The largest buyer was Bellevue Group, adding an estimated $127M. The largest seller was American Century Companies, cutting an estimated $29M.
- 290 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $7.7B of Alnylam Pharmaceuticals stock for Q2 2019, down 15% quarter-over-quarter.
- 40 funds opened new Alnylam Pharmaceuticals positions in Q2 2019 and 37 closed out, a net change of +3 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2019 was Bellevue Group, an estimated $127M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2019 was American Century Companies, an estimated $29M sold.
Based on aggregated 13F filings for Q2 2019.